NeuroMetrix to Introduce Quell® Fibromyalgia at the American College of Rheumatology 2022 Annual Meeting
08 nov. 2022 09h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) will introduce Quell Fibromyalgia at the American College of Rheumatology Annual Meeting, ACR Convergence 2022, on...
NeuroMetrix Announces Strategic Launch of Quell Fibromyalgia
03 nov. 2022 09h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced the strategic launch of its Quell® Fibromyalgia device through the Pathfinder Program. Quell...
NeuroMetrix Reports Q3 2022 Financial Results
20 oct. 2022 07h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and nine-month period ended September 30, 2022. The...
NeuroMetrix, Inc. Announces Date for Third Quarter 2022 Financial Results Conference Call
12 oct. 2022 15h47 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 third quarter financial results before the opening of the market on...
NeuroMetrix Names Jonathan Breck Harmel as National Director of Sales for its Emerging Prescription Neurotherapeutics Business
01 sept. 2022 09h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has appointed Jonathan "Breck" Harmel as National Director of Sales, Neuromodulation. Mr....
NeuroMetrix Reports Q2 2022 Financial Results
21 juil. 2022 07h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., July 21, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and six months period ended June 30, 2022. The...
NeuroMetrix, Inc. Announces Date for Second Quarter 2022 Financial Results Conference Call
14 juil. 2022 11h32 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., July 14, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 second quarter financial results before the opening of the market on...
NeuroMetrix Appoints Brad Fluegel to its Board of Directors
28 juin 2022 09h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., June 28, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced the appointment of Bradley M. Fluegel to its Board of Directors, effective as of July 1, 2022. Mr....
NeuroMetrix Reports that Quell® Wearable Neuromodulation Device has Received FDA De Novo Authorization as First Non-Pharmacological Treatment for Fibromyalgia
19 mai 2022 09h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced U.S. Food and Drug Administration (FDA) De Novo authorization to market the Quell neuromodulation...
NeuroMetrix Reports Q1 2022 Financial Results
26 avr. 2022 07h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2022. The Company's mission is to...